Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action
- 1 December 2020
- journal article
- research article
- Published by Elsevier BV in Thrombosis Research
- Vol. 196, 313-317
- https://doi.org/10.1016/j.thromres.2020.09.013
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumoniaJournal of Thrombosis and Haemostasis, 2020
- More than an anticoagulant: Do heparins have direct anti-inflammatory effects?Thrombosis and Haemostasis, 2017
- Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016Critical Care Medicine, 2017
- Low anticoagulant heparin blocks thrombin-induced endothelial permeability in a PAR-dependent mannerVascular Pharmacology, 2014
- A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction ScoreJournal of Thrombosis and Haemostasis, 2010
- Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligandsAmerican Journal of Physiology-Cell Physiology, 2010
- Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trialThe Lancet, 2009
- Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settingsJournal of Thrombosis and Haemostasis, 2006
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patientsJournal of Thrombosis and Haemostasis, 2005